Well Referenced

Tag: intravenous mistletoe

Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study

This large-scale observational study evaluated the safety of intravenous mistletoe preparations (Helixor, Abnoba viscum, Iscador) in 475 oncology patients. Over 4,500 infusions were analyzed. Adverse drug reactions (ADRs) were reported in 4.6% of patients, with 59.4% of these being mild and 40.6% moderate; no severe ADRs were observed. ADRs occurred

Read More »
June 26, 2025 No Comments

Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer

This phase I dose-escalation trial investigated the safety and tolerability of intravenous mistletoe extract (Helixor® P) in 21 patients with advanced, treatment-resistant malignancies. Doses ranged from 200 to 2000 mg weekly over a 3-week period, with a 9-week extension for high-dose patients. The maximum tolerated dose was not reached. One

Read More »
June 26, 2025 No Comments

Intravenous Mistletoe Treatment in Integrative Cancer Care: A Qualitative Study Exploring the Procedures, Concepts, and Observations of Expert Doctors

This 2016 qualitative study explored the use of intravenous mistletoe therapy (MT) in integrative cancer care through interviews with 35 experienced physicians specializing in anthroposophic medicine. The study found that MT is employed to stabilize disease, induce fever, enhance quality of life, and improve the tolerability of conventional treatments. Physicians

Read More »
June 26, 2025 No Comments